DVC

DVC appears in the source data with website dvc.ai and shares a LinkedIn handle and Crunchbase profile with Davidovs Venture Capital, suggesting they are the same fund operating under multiple brand names or closely related vehicles. The .ai domain hints at an AI-thesis emphasis in current positioning. For healthcare AI founders, DVC is most plausibly a generalist early-stage AI-focused investor without confirmed healthcare specialization, with the same caveats as the Davidovs profile. Plausible check sizing is $100K to $1M at seed, typically as a participant rather than lead. The most likely fit, if any, is for AI infrastructure, applied AI, or AI-native vertical software companies where healthcare is one of several possible end markets, rather than for clinically deep, regulated, or capital-intensive healthcare plays. Founders building therapeutics, regulated devices, or care delivery should not pursue DVC and should look to specialist healthcare AI investors instead. The firm’s value-add is harder to predict without disclosed thesis or recent portfolio data; founders should ask directly during initial outreach about AI-specific capabilities and any healthcare track record. Entry path is LinkedIn outreach to the partners, the website inquiry form, or warm referral from a portfolio CEO. Founders should reverse-diligence by asking for recent investments, fund size, and ownership targets before significant pitch preparation. Given the apparent overlap with Davidovs Venture Capital, founders should also clarify which entity they are engaging with to avoid duplicate or confused outreach. Be honest about the data gap: at this profile, founder time should be limited until clearer signals of thesis alignment surface, and prioritize disclosed-thesis healthcare AI investors above this profile.